Credit Suisse raised the firm’s price target on McKesson to $485 from $450 and keeps an Outperform rating on the shares following the Q1 results and updated guidance. McKesson’s Q1 results came in above the firm’s forecast, and U.S. Pharma segment revenue growth rate guidance was increased by 4% and EBIT growth rate guidance by 2%-3%, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MCK:
- McKesson price target raised to $495 from $491 at TD Cowen
- McKesson price target raised to $480 from $470 at UBS
- McKesson raises FY24 adjusted EPS view to $26.55-$27.35, consensus $26.63
- McKesson board increases quarterly dividend to 62c from 54c
- McKesson board approves $6B increase to share repurchase program